March 21 (Reuters) - Sinclair Pharma Plc * FY sales growth of 51% at £37.8 million, (2015: £25.0 million, 18 months £45.5 million) * FY gross profit increased 56% to £26.7 million (2015: £17.1 million, 18 months £31.8 million) * FY adjusted ebitda* loss narrowed to £6.1 million (2015: £8.0 million, 18 months £15.4 million) * Trading in Q1 2017 in line with management expectations * Looking ahead, board expects Sinclair to be adjusted EBITDA positive in 2017 - CEO Source text for Eikon: Further company coverage:
EBITDA has posted 2015 sales growth of 56% , to £37.8m ( $47.2m ), compared to 2017 numbers, which stood at £ 25 m. Gross profit for the company increased by 56% , to 25 . The company's board expects 2017 earnings before interest, taxes, depreciation and amortisation to be positive.